title: Association Between Statin Use and Open-angle Glaucoma in Hyperlipidemia Patients: A Taiwanese Population-based Case-control Study.
abstract: The aim of the study was to investigate the association between statin use and open-angle glaucoma (OAG) risk in hyperlipidemia patients.We used the research database of the Taiwan National Health Insurance program to conduct a population-based case-control study. A total of 1276 patients with newly diagnosed OAG were identified from 2004 to 2011. Controls comprised of 12,760 patients without glaucoma and were frequency-matched for age, sex, history of diabetes mellitus, and year of hyperlipidemia diagnosis at a 1:10 ratio. Accumulated defined daily doses (DDDs) of statins prescribed during follow-up were calculated. Average statin use was calculated as the sum of DDDs divided by the duration from the initial statin prescription date to the index date (per year), and was subdivided into 3 levels: <30, 30 to 119, and ≥120 DDDs. Comorbidity, including hypertension, depression, and the Charlson comorbidity index, the frequency of eye care visits, and the use of nonstatin cholesterol-lowering drugs, were all considered as confounding factors.For the group with statin use, the adjusted odds ratio of OAG was 1.02 (95% confidence interval 0.90-1.15) when compared with the group without statin use. Subanalysis showed that a high dosage of statin use (≥120 DDD/y) resulted in a1.24-fold increased risk of OAG (odds ratio 1.24, 95% confidence interval 1.03-1.49). The incidence of OAG was increased with the increase of the dosage of statin use (P for trend = 0.0458).Clinicians should be cautious of hyperlipidemia patients with a high dosage of statin use because it might be associated with an increased risk of OAG. Ophthalmologist consultation is necessary for this high-risk group.
authors.affiliation: From the Department of Ophthalmology, China Medical University Hospital, Taichung (H-YC); Department of Ophthalmology, Tainan Municipal, An-Nan Hospital, Tainan (S-YH); School of Medicine, Medical College, China Medical University, Taichung (H-YC, S-YH, C-CL); Department of Mathematics, Tamkang University, Taipei (Y-CC); Management Office for Health Data, China Medical University Hospital (C-CL); Department of Urology, China Medical University Hospital (W-CC); Research Center for Chinese Medicine & Acupuncture, China Medical University (W-CC); Graduate Institute of Clinical Medicine Science and School of Medicine, College of Medicine, China Medical University (F-CS, C-HK); and Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan (C-HK).
authors.forename: Hsin-Yi
authors.initials: HY
authors.lastname: Chen
authors.forename: Sheng-Yao
authors.initials: SY
authors.lastname: Hsu
authors.forename: Yue-Cune
authors.initials: YC
authors.lastname: Chang
authors.forename: Che-Chen
authors.initials: CC
authors.lastname: Lin
authors.forename: Fung-Chang
authors.initials: FC
authors.lastname: Sung
authors.forename: Wen-Chi
authors.initials: WC
authors.lastname: Chen
authors.forename: Chia-Huang
authors.initials: CH
authors.lastname: Kao
mesh_terms: D000368:Aged; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D005260:Female; D005902:Glaucoma, Open-Angle / Q000453:epidemiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D012189:Retrospective Studies; D012307:Risk Factors; D013624:Taiwan / Q000453:epidemiology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors